Long-Term Combined rIFN-Alpha-2A and Zidovudine Therapy for HIV-Associated Kaposi's Sarcoma: Clinical Consequences and Side Effects
- 1 December 1990
- journal article
- clinical trial
- Published by Elsevier BV in Journal of Investigative Dermatology
- Vol. 95 (6), S170-S175
- https://doi.org/10.1111/1523-1747.ep12875494
Abstract
No abstract availableKeywords
This publication has 46 references indexed in Scilit:
- The safety of intravenous chemotherapy and zidovudine when treating epidemic Kaposiʼs sarcomaAIDS, 1989
- Sir,AIDS, 1989
- Interferons in dermatologyJournal of the American Academy of Dermatology, 1989
- AIDS-associated Kaposi's sarcoma: Variables associated with survivalJournal of the American Academy of Dermatology, 1988
- Angioproliferative Changes in Clinically Noninvolved, Perilesional Skin in AIDS-Associated Kaposi’s SarcomaDermatology, 1987
- Prevalence of Kaposi's Sarcoma among Patients with AIDSNew England Journal of Medicine, 1985
- Kaposi's Sarcoma among Four Different AIDS Risk GroupsNew England Journal of Medicine, 1984
- Preliminary Observations on the Effect of Recombinant Leukocyte a Interferon in Homosexual Men with Kaposi's SarcomaNew England Journal of Medicine, 1983
- Opportunistic Infections and Kaposi's Sarcoma in Homosexual MenNew England Journal of Medicine, 1981
- Disseminated Kaposi's sarcoma syndrome in young homosexual menJournal of the American Academy of Dermatology, 1981